High SVR Rates with SMV + SOF in HCV GT1 and GT4 Patients with Cirrhosis or Advanced Fibrosis: A Real Practice Analysis from a Large Regional Database in Tuscany, Italy

Salomoni, E; Gianni, Elena; Gragnani, Laura; Oliveri, F.; Brunetto, M.R.; Luchi, Sauro; Bartolozz, D.; Forte, Paolo; Sani, S H Danesh; Blanc, P; Sacco, Rosario; Zignego, A.L.; Luca, Andrea De; Tacconi, Danilo; Aquilini, Donatella; Menichetti, F.; Catalani, Claudio; Nencioni, Cesira; Carrai, P; Chigiotti, Silvia; Colombatto, P.

doi:10.1016/s0168-8278(16)01484-7

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

2017

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Aghemo et al., in patients with compensated cirrhosis and treated with a combination of SOF plus SIM with or without RBV, SVR was 93%. Similarly, in a study of Salomoni et al., SVR was 93.6% in cirrhotic patients treated with SOF plus SMV with or without RBV. In all of these studies, genotype 1b was the most representative HCV genotype (60%), and the majority of patients analysed had compensated cirrhosis.…”

Section: Discussionmentioning

confidence: 94%